22
BRUSSELS, July 01, 2026 (GLOBE NEWSWIRE) — SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from Hansa Biopharma.
“Adding Idefirix to the SERB portfolio reflects…
